Insmed to present new data from across its respiratory portfolio at the american thoracic society 2024 international conference

—additional data from arise study evaluating the impact of arikayce on microbiologic outcomes in patients with newly diagnosed or recurrent mac lung disease to be presented as late-breaker— —data to be presented from arise examining change in patient-reported respiratory symptoms— bridgewater, n.j. , march 27, 2024 /prnewswire/ -- insmed incorporated (nasdaq: insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will present nine abstracts from across its respiratory portfolio at the american thoracic society (ats) 2024 international conference, taking place may 17-22, 2024, in san diego.
INSM Ratings Summary
INSM Quant Ranking